HER2/MUC1 bispecific CAR for breast cancer cell therapy in vitro [71], an EGFR/EpCAM/HER2 triple-specific CAR against Raji lymphoma cells engineered to express TAAs [72], and a HER2/IL-13Ra2 bispecific CAR for the treatment of a glioma xenograft in vivo have shown promising results [73]. Here, ERBB2 is linked to central nervous system cancer.